

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

1a. REPORT SECURITY CLASSIFICATION UNCLASSIFIED		1b. RESTRICTIVE MARKINGS DTIC FILE COPY	
2a. SECURITY CLASSIFICATION AUTHORITY AD-A212 532		3. DISTRIBUTION / AVAILABILITY OF REPORT	
6a. NAME OF PERFORMING ORGANIZATION WRAIR, DEPT OF IMMUNOLOGY		7a. NAME OF MONITORING ORGANIZATION WALTER REED ARMY INSTITUTE OF RESEARCH	
6b. OFFICE SYMBOL (If applicable) SGRD-UWF-D		7b. ADDRESS (City, State, and ZIP Code) Library/Reprint Department Washington, DC 20307-5100	
6c. ADDRESS (City, State, and ZIP Code) Walter Reed Army Institute of Research Dept of Immunology, Washington, DC 20307-5100		7c. ADDRESS (City, State, and ZIP Code) Library/Reprint Department Washington, DC 20307-5100	
8a. NAME OF FUNDING / SPONSORING ORGANIZATION Ft Detrick, Frederick, MD		8b. OFFICE SYMBOL (If applicable)	
9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER		10. SOURCE OF FUNDING NUMBERS	
8c. ADDRESS (City, State, and ZIP Code) Finance & Accounting Officer Ft Detrick, Frederick, MD 21701-5000		PROGRAM ELEMENT NO.	
		PROJECT NO.	
		TASK NO.	
		WORK UNIT ACCESSION NO.	
11. TITLE (Include Security Classification) Interaction Of Malaysia Sera With Plasmodium Vivax Sporozoite Antigen			
12. PERSONAL AUTHOR(S) Melinda Lee, W. Ripley Ballou, Gail Wasserman, and George E. Lewis			
13a. TYPE OF REPORT Manuscript		13b. TIME COVERED FROM _____ TO _____	
14. DATE OF REPORT (Year, Month, Day)		15. PAGE COUNT	
16. SUPPLEMENTARY NOTATION			
17. COSATI CODES		18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)	
FIELD	GROUP	SUB-GROUP	
19. ABSTRACT (Continue on reverse if necessary and identify by block number) Abstract unavailable. The (1) copy has been sent to the publisher.			
20. DISTRIBUTION / AVAILABILITY OF ABSTRACT ☐ UNCLASSIFIED/UNLIMITED ☐ SAME AS RPT. ☐ DTIC USERS		21. ABSTRACT SECURITY CLASSIFICATION	
22a. NAME OF RESPONSIBLE INDIVIDUAL Dr. W. Ripley Ballou		22b. TELEPHONE (Include Area Code) (202) 378-3659	
		22c. OFFICE SYMBOL SGRD-UWF-D	

INTERACTION OF MALAYSIAN SERA WITH *PLASMODIUM VIVAX* SPOROZOITE ANTIGEN

MELINA A LEE, DON R. DAVIS, W. RIPLEY BALLOU,* GAIL FOLENA-WASSERMAN†
AND GEORGE E. LEWIS

*Malaria Research Group, United States Army Medical Research Unit,
Institute for Medical Research, Jalan Pahang, 50588 Kuala Lumpur, Malaysia,*

**Department of Immunology, Walter Reed Army Institute of Research, Washington, DC 20307,
and †Department of Protein Biochemistry, SK&F Laboratories, Swedeland, Pennsylvania*

Abstract. A seroepidemiologic survey of *Plasmodium vivax* and *Plasmodium falciparum* transmission was conducted in 94 Orang Asli children and adults. The prevalence of malaria was 46% in this population, and infections due to *P. vivax* and *P. falciparum* occurred with equal frequency. Multi-species infection was common, particularly in children <10 years of age. Circumsporozoite (CS) antibodies to *P. vivax* were detected by ELISA, using the recombinant protein NS1₈₁V20, in sera from 53-95% of all subjects in this study. The specificity of reactivity to NS1₈₁V20 was confirmed by immunofluorescence using air-dried sporozoites. CS antibodies to *P. falciparum* were present in <50% of the population <30 years of age. These data support further testing of this protein as a candidate vivax vaccine.

Plasmodium vivax is the major cause of relapsing malaria in most malarious regions except sub-Saharan Africa. Immunization with irradiated *P. vivax* sporozoites has been shown to induce protection against experimental sporozoite challenge and to elicit antibodies directed against immunodominant epitopes of the circumsporozoite (CS) protein that mediates in vitro reactions thought to correlate with protective immunity.¹ Cloning and sequencing of the gene encoding the CS protein of *P. vivax* has led to the development of subunit vaccines.²⁻⁴ As in *P. falciparum*, the CS protein of *P. vivax* consists of immunodominant epitopes repeated in tandem flanked by nonrepeating sequences, some of which are conserved among malaria species. We demonstrate that NS1₈₁V20, a recombinant fusion protein expressed in *E. coli* and containing the entire central repeat portion of the vivax CS protein, is specifically recognized by sera obtained from persons with lifetime exposure to *P. vivax* sporozoites. Our data indicate that the immunodominant CS epitopes of *P. vivax* sporozoites are highly immunogenic for humans and suggest that NS1₈₁V20 is a suitable candidate for further clinical trials.

MATERIALS AND METHODS

Human sera

Monthly malariametric surveys were conducted in the Pos Legap area of Perak State, Malaysia, August-November 1986. The aboriginal population living in this region employs little, if any, routine malaria prophylaxis or effective malaria control measures. Consistent population point prevalences of 38-40% for infection with *Plasmodia* of one or more species were found. Subsequent surveys substantiated year-round transmission of *P. falciparum*, *P. vivax*, and *P. malariae*. To test the hypothesis that prolonged natural exposure to *P. vivax* sporozoites induces antibodies that react with NS1₈₁V20, we randomly selected 94 serum samples from among 595 subjects aged 6 months-53 years. Nonimmune sera obtained from 30 healthy U.S. servicemen with no known exposure to malaria served as normal controls.

Enzyme-linked immunosorbent assay

Enzyme-linked immunosorbent assays (ELISAs) were performed as described⁵ except that plates were coated with NS1₈₁V20 at a concentration of 0.1 µg/well for the detection of anti-

Accepted 29 May 1988.

TABLE 1

Distribution and prevalence of malaria by species among 94 Orang Asli as determined by microscopic evaluation of thick smears of peripheral blood

Age (years)	n	Pf	Pv	Pm	Pf/Pv	Pv/Pm	Pf/Pm	Pv/Pf/Pm	Prevalence
≤4	17	2	0	0	3	3	3	2	76%
5-9	19	3	2	0	3	0	0	2	53%
10-19	15	0	4	0	2	0	0	0	40%
20-29	15	1	3	0	2	0	0	0	40%
30-39	16	3	1	1	0	1	0	0	38%
>40	12	2	1	1	1	0	0	0	41%
	94	11	10	2	11	4	3	4	46%

n = Number tested in each age group.

Pf = *P. falciparum*, Pv = *P. vivax*, Pm = *P. malariae*.

bodies to the *P. vivax* CS protein, and with R32tet₃₂ for the detection of *P. falciparum* CS antibodies. Sera were diluted 1:100, and the absorbance of sera in wells without antigen was subtracted from the absorbance of sera in wells with antigen to control for background reactivity. Positive reactions for both vivax and falciparum assays were defined as an optical density (OD) exceeding the mean plus 3 standard deviations (SD) of the 30 normal control sera (0.115, NS1₈₁V20; 0.101, R32tet₃₂).

Immunofluorescent assays

We selected 30 immune sera for characterization by immunofluorescent assays (IFAs). Sera diluted 1:40 were assayed using air-dried salivary gland sporozoites from the Chesson strain of *P. vivax* and the NF54 strain of *P. falciparum* as previously described.⁶ Results were graded 0-4+, with 0 indicating no fluorescence and 4+ indicating intense fluorescence along the entire sporozoite. Antibodies against malaria blood stage antigens were assayed using *P. cynomolgi* parasitized monkey erythrocytes (to detect antibodies against *P. vivax*) or *P. falciparum* infected human erythrocytes.⁷

Peripheral blood smears

Peripheral blood smears were obtained and prepared from each of the 94 individuals in the study at the same time that sera were drawn. For each specimen, 200 oil immersion fields (1,000×) of a Giemsa stained thick smear were examined by an experienced microscopist.

RESULTS

Malaria was hyper- to holoendemic in the study population (Table 1). Similar rates were found for *P. vivax* (30/46, 65%) and *P. falciparum* (29/46, 63%). Multi-species infections were more common in children <10 than in older subjects (16/22 vs. 6/22, $\chi^2 = 8.712$, $P < 0.01$), as were infections due to *P. malariae* (10/13 vs. 3/13, $\chi^2 = 5.254$, $P = 0.02$).

The proportion of subjects having CS antibodies and the mean OD by ELISA of those sera to both *P. vivax* and *P. falciparum* CS proteins increased with age (Figs. 1, 2). The mean OD of *P. vivax* CS antibodies was highest in subjects ≥30 years of age. These individuals also had a lower incidence of *P. vivax* infections compared to subjects <30 years of age (4/28 vs. 26/66, $\chi^2 = 6.52$, $P = 0.01$). Despite the fact that equal numbers of individuals in the total population were infected with *P. falciparum* and *P. vivax*, more than 50% of the subjects in each age group had antibodies to *P. vivax* CS protein, whereas seroconversion of ≥50% of the subjects to *P. falciparum* CS protein occurred only after age 30. As shown in Figure 3, the results of ELISA using the recombinant antigens correlated well with IFA using air-dried sporozoites ($r = 0.743$, *P. vivax*; $r = 0.621$, *P. falciparum*). Blood stage antibodies to both *P. falciparum* and *P. vivax* were present in all individuals, and titers increased with age (Fig. 4).

DISCUSSION

This seroepidemiologic study identified an aboriginal Malaysian population with a high prevalence of *P. vivax* and *P. falciparum* infections.




FIGURE 1. Antibody responses to *P. vivax* CS antigen as determined by ELISA using NS1₈₁V20 as capture antigen. The percent of positive sera (●) and the mean OD (▲) are shown for each age group.

Although there are numerous reports describing CS antibody responses to the immunodominant repeat epitopes of *P. falciparum*, similar data for *P. vivax* responses are limited. A better understanding of the human immune response to this CS protein will be important to sporozoite vaccine development for *P. vivax*. Sera from a majority of these subjects reacted specifically by ELISA with the recombinantly produced *P. vivax* CS protein NS1₈₁V20. This antigen, produced in *E. coli*, is a highly purified protein consisting of 81 amino acids from the nonstructural protein 1 of influenza A fused N-terminal to the entire immunodominant central repeat portion (180 amino acids) of the *P. vivax* CS Protein (G. F. Wasserman, personal communication). Preclinical studies with the vaccine demonstrated that immune sera from mice, rabbits, and non-human primates react with intact *P. vivax* sporozoites by IFA (W. R. Ballou, personal communication). These data, together with the high proportion of subjects in this human population having antibodies that react with NS1₈₁V20, indicate that important epitopes on the molecule have not been adversely affected either by expression in a prokaryotic system (*E. coli*) or by the presence of the NS1 portion of the fusion protein. Furthermore, the absence of nonspecific reactivity to NS1₈₁V20 in 30 normal control sera indicates that antibodies to NS1 are not common and suggests that the possibility of carrier mediated suppression of antibody responses to the CS repeats will be unlikely. These results are consistent with data indicating that convalescent sera




FIGURE 2. Antibody responses to *P. falciparum* CS antigen as determined by ELISA using R32tet₃₂ as capture antigen. The percent of positive sera (●) and the mean OD (▲) are shown for each age group.

from influenza A patients fail to react with NS1₈₁V20 by ELISA (D. G. Gordon, Department of Immunology, Walter Reed Army Institute of Research, Washington, DC, personal communication). Antibody responses to the *P. falciparum* CS antigen are consistent with those of similar studies conducted elsewhere demon-




FIGURE 3. Scattergram showing the relationship between ELISA OD and IFA using air-dried sporozoites of *P. vivax* (A) and *P. falciparum* (B). The correlation coefficients ELISA activity and IFA score are shown.




FIGURE 4. Reciprocal geometric mean titers (GMT) of blood stage antibodies to *P. falciparum* (●) and *P. vivax*/*P. cynomolgi* (▲) antigens as determined by IFA. Positive responses were defined as those with RGMT $\geq 1:40$.

strating an age-dependent acquisition of CS antibodies in a majority of exposed individuals.⁸⁻¹⁰

Despite nearly equal prevalence rates for *P. falciparum* and *P. vivax* malaria, a higher proportion of the study subjects had antibodies to *P. vivax* CS protein than had *P. falciparum* CS antibodies. This was true for all age groups. One possible explanation is that *P. vivax* sporozoites may be inherently more immunogenic for this population than are *P. falciparum* sporozoites. While we cannot exclude differences in antigenic exposure (i.e., greater numbers of sporozoites injected or prolonged exposure to CS proteins during the exoerythrocytic stages of *P. vivax*) higher seroconversion rates to *P. vivax* CS repeat epitopes may reflect less genetic restriction of immune response to this protein as compared to the CS repeats of *P. falciparum*.¹⁰ This may be due to the larger number of amino acids per repeat (9 vs. 4) or the presence of sequence heterogeneity [GlnProAlaGlyAspArgAla (Ala/Asp) Gly] in 50% of the *P. vivax* repeats.² Alternatively, the *P. vivax* CS protein may contain more widely recognized T cell epitopes in the nonrepeat flanking regions than those that have been defined for *P. falciparum*.¹¹

Although the mean OD of *P. vivax* CS antibodies increased with age, there was a lower prevalence of *P. vivax* infections after age 30, perhaps due to low parasite densities not detected by peripheral blood smears. This study does not suggest that CS antibodies are protective against natural transmission of *P. vivax* sporozoites. This study has, however, identified a pop-

ulation at high risk for *P. vivax* malaria that may be suitable for further analysis of protective immune responses.

ACKNOWLEDGMENTS

We thank Lailanor bin Ibrahim, Director of Gombak Hospital, for his support; Imogene Schneider and William E. Collins for sporozoites; and Sally Mak and Saravana Ram for technical assistance.

This research was supported by grant DAMD117-88-Z-8014 from the U.S. Army Medical Research and Development Command, Fort Detrick, MD 21701-5012.

REFERENCES

1. Clyde DF, 1975. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. *Am J Trop Med Hyg* 24: 397-401. UI:75222895
2. McCutchan TF, Lal AA, de la Cruz VF, Miller LH, Maloy WL, Charoenvit Y, Beaudoin RL, Guerry P, Wistar R, Hoffman SL, and others, 1985. Sequence of the immunodominant epitope for the surface protein on sporozoites of *Plasmodium vivax*. *Science* 230: 1381-1383. UI:86070222
3. Arnot DE, Barnwell JR, Tam JP, Nussenzweig V, Nussenzweig RS, Enea V, 1985. Circumsporozoite protein of *Plasmodium vivax*: gene cloning and characterization of the immunodominant epitope. *Science* 230: 815-818. UI:86044510
4. Barr PJ, Gibson HL, Enea V, Arnot DE, Hollingdale MR, Nussenzweig V, 1987. Expression in yeast of a *Plasmodium vivax* antigen of potential use in a human malaria vaccine. *J Exp Med* 165: 1160-1171. UI:87168195
5. Hoffman SL, Oster CN, Plowe CV, Woollett GR, Beier JC, Chulay JD, Wirtz RA, Hollingdale MR, Mugambi M, 1987. Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. *Science* 237: 639-642. UI:87263430
6. Ballou WR, Hoffman SL, Sherwood JA, Hollingdale MR, Neva FA, Hockmeyer WT, Gordon DM, Schneider I, Wirtz RA, Young JF, and others, 1987. Safety and efficacy of a recombinant DNA *Plasmodium falciparum* sporozoite vaccine. *Lancet* i: 1277-1281. UI:87227707
7. Collins WE, Skinner JC, 1972. The indirect fluorescent antibody test for malaria. *Am J Trop Med Hyg* 21: 690-695. UI:73011609
8. Drulhe P, Pradier O, Marc JP, Miltgen F, Mazier D, Parent G, 1986. Levels of antibodies to *Plasmodium falciparum* sporozoite surface antigens reflect malaria transmission rates and are per-

- sistent in the absence of reinfection. *Infect Immun* 53: 393-397. UI:86276928
9. Del Giudice G, Engers HD, Tougne C, Biro SS, Weiss N, Verdini AS, Pessi A, Degremont AA, Freyvogel TA, Lambert P, and others, 1987. Antibodies to the repetitive epitope of *Plasmodium falciparum* circumsporozoite protein in a rural Tanzanian community: a longitudinal study of 132 children. *Am J Trop Med Hyg* 36: 203-212. UI:87154099
 10. Good MF, Berzofsky JA, Maloy WL, Hayashi Y, Fujii N, Hockmeyer WT, Miller LH, 1986. Genetic control of the immune response in mice to a *Plasmodium falciparum* sporozoite vaccine. Widespread nonresponsiveness to single malaria T epitope in highly repetitive vaccine. *J Exp Med* 164: 655-660. UI:86253098
 11. Good MF, Pombo D, Quakyi IA, Riley EM, Houghten RA, Menon A, Alling DW, Berzofsky JA, Miller LH, 1988. Human T-cell recognition of the circumsporozoite protein of *Plasmodium falciparum*: immunodominant T-cell domains map to the polymorphic regions of the molecule. *Proc Natl Acad Sci USA* 85: 1199-1203. UI: 88125003

Accession For	
NTIS GRA&I	☒
DTIC TAB	☒
Unannounced	☐
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1 20	

